Breast Cancer

Multiple targeted therapies/sequencing possibilities are available following elacestrant’s approval for patients with breast cancer, Maxwell Lloyd, MD, said.

Since elacestrant’s emergence in the real-world setting, it has demonstrated superior efficacy outcomes compared with what the EMERALD study found.

Panelists discuss how emerging targeted therapies, including novel PI3K inhibitors and combination treatments, are advancing precision pathways in HR positive (HR+)/HER2 negative (HER2-) breast cancer, offering new hope for personalized treatment and improved patient outcomes.

Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.

Patients with ER+/HER2– advanced breast cancer saw positive efficacy and safety data following treatment from the SERENA-1 trial.

Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.

Ultra-sensitive ctDNA testing identified ctDNA at baseline in patients with HR–positive breast cancer, results from the PELOPS trial showed.

Atezolizumab with chemotherapy did not yield a significant increase to event-free survival compared with placebo with chemotherapy, 85.2% vs 81.9%, respectively.

Of 18 patients with BRCA-mutated ER+/HER2– breast cancer, 3 had a pathological complete response when treated with niraparib plus dostarlimab.

The phase 3 CamRelief study reported a pathologic complete response rate of 56.8% for camrelizumab plus chemo compared with 44.7% for chemo alone.

Data from the RIGHT Choice study showed that ribociclib/ET yielded efficacy benefits for luminal B/HER2E breast cancer vs combination chemotherapy.

Palbociclib combination therapy elicited a progression-free survival of 44.3 months compared with the 29.1 months of SOC in HR+, HER2+ breast cancer.

Data from the EMBER-3 trial showed improved progression-free survival with imlunestrant with or without abemaciclib vs SOC in ER+/HER2– breast cancer.

Elascestrant with abemaciclib elicited an overall response rate of 18% in ER+/HER2– Breast Cancer, results from the 2 trials show.

When compared with endocrine therapy, radiation therapy improved quality of life and adverse effects data, the phase 3 EUROPA study showed.

Analysis of NRG/RTOG 9804 and E5194 trials found tamoxifen significantly reduced invasive ipsilateral breast recurrence in patients with “good risk” DCIS treated without RT.

Active monitoring had similar rates of invasive cancer in the ipsilateral breast as guideline concordant care for the low-risk DCIS population.

Real-world data from the P-VERIFY study didn’t find any notable OS improvements between multiple CDK4/6 inhibitor combos in metastatic breast cancer.

During an FDA Special Session, field experts talked about the NATALEE trial and further information gathering on adjuvant ribociclib in breast cancer.

For patients with HR–positive/HER2-negative breast cancer, neoadjuvant patritumab deruxtecan with or without letrozole showed antitumor activity.

Data show no significant differences in pCR rates across treatment arms in the phase 2 FASCINATE-N trial.

Six-year data from the OlympiA trial support olaparib as a standard of care in BRCA-mutated, high-risk, HER2-negative primary breast cancer.

Time to next treatment was slightly higher with elacestrant for patients with HR+/HER2–, ESR1-mutant breast cancer vs PFS in a phase 3 trial.